BiotechTube

eftilagimod alpha + pembrolizumab (KEYTRUDA®)

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HNSCC

Conditions

HNSCC

Trial Timeline

Aug 27, 2021 → Nov 5, 2025

NCT ID
NCT04811027

About eftilagimod alpha + pembrolizumab (KEYTRUDA®)

eftilagimod alpha + pembrolizumab (KEYTRUDA®) is a phase 2 stage product being developed by Merck for HNSCC. The current trial status is completed. This product is registered under clinical trial identifier NCT04811027. Target conditions include HNSCC.

What happened to similar drugs?

0 of 2 similar drugs in HNSCC were approved

Approved (0) Terminated (1) Active (1)
🔄Ivonescimab 10 mg/kg + Ligufalimab + Pembrolizumab (KEYTRUDA ®)AkesoPhase 3
❌LymphoseekNavidea BiopharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04811027Phase 2Completed
NCT03625323Phase 2Completed

Competing Products

18 competing products in HNSCC

See all competitors
ProductCompanyStageHype Score
AZD2936AstraZenecaPhase 2
42
pepinemab + pembrolizumabMerckPhase 1/2
32
PembrolizumabMerckPhase 2
39
Pembrolizumab, CetuximabMerckPhase 2
35
Cetuximab/avelumabMerckPhase 2
42
Ulevostinag + PembrolizumabMerckPhase 2
35
Motolimod + NivolumabBristol Myers SquibbPhase 1
21
Nivolumab + Cisplatin + CetuximabBristol Myers SquibbPhase 1
29
Nivolumab + Relatlimab + IpilimumabBristol Myers SquibbPhase 2
42
Ivonescimab 10 mg/kg + Ligufalimab + Pembrolizumab (KEYTRUDA ®)AkesoPhase 3
47
FDC fianlimab+cemiplimab + Cemiplimab + PlaceboRegeneron PharmaceuticalsPhase 2
42
GTAEXS617 + SoCRecursion PharmaceuticalsPhase 1/2
33
Ficerafusp alfa + PembrolizumabBicara TherapeuticsPhase 2
36
INBRX-106 + PembrolizumabInhibrx BiosciencesPhase 2/3
39
Tipifarnib + AlpelisibKura OncologyPhase 1/2
26
STRO-004 + PembrolizumabSutro BiopharmaPhase 1
26
DP CD8 TIL + DP CD8 TIL KD + Low dose IL-2Phio PharmaceuticalsPhase 1
23
LymphoseekNavidea BiopharmaceuticalsPhase 3
22